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Abstract
For a long time, gene editing had been a scientific concept, which was limited to a few applications. With recent develop-
ments, following the discovery of TALEN zinc-finger endonucleases and in particular the CRISPR/Cas system, gene editing 
has become a technique applicable in most laboratories. The current gain- and loss-of function models in basic science are 
revolutionary as they allow unbiased screens of unprecedented depth and complexity and rapid development of transgenic 
animals. Modifications of CRISPR/Cas have been developed to precisely interrogate epigenetic regulation or to visualize 
DNA complexes. Moreover, gene editing as a clinical treatment option is rapidly developing with first trials on the way. This 
article reviews the most recent progress in the field, covering expert opinions gathered during joint conferences on genome 
editing of the German Cardiac Society (DGK) and the German Center for Cardiovascular Research (DZHK). Particularly 
focusing on the translational aspect and the combination of cellular and animal applications, the authors aim to provide 
direction for the development of the field and the most frequent applications with their problems.
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Introduction
It is estimated that approximately 5% of newborns will suffer 
from a genetic disorder. This suggests that almost 400 mil-
lion people worldwide are affected by genetic diseases [157], 
and tailored drugs and/or genetic approaches are lacking for 
most of them. Gene therapy and especially gene editing are 
the most rational and mechanistic approaches to treat genetic 
diseases. Gene editing therefore aims on correcting muta-
tions in a gene, to delete or replace parts of a gene or to alter 
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gene expression. Since the discovery of the genetic code, 
gene editing has, however, been more a theoretical possibil-
ity than practical reality. Limited to a few applications and 
utilizing imperfect tools, like retrovirus, gene editing, for a 
long time, did not keep its promises, but this has changed 
within recent years [78].
In addition to the clinical benefit of gene editing, the 
technology is also important for the production of trans-
genic crops and animals. In basic and translational sciences, 
gene editing also allows specific modifications of genes and 
manipulation of gene expression in practically all life forms, 
ranging from cells and organs to living animals. Contrary to 
transient gain or loss-of-function approaches, like RNAi or 
plasmid-based overexpression, the effects of gene editing 
can be permanent, and are therefore less prone to artefacts. 
The technology, however, also has limitations, like the need 
of shuttle systems and potential off-target effects.
Within recent years, a series of discoveries has revolu-
tionized the toolset to edit the cellular genome. Program-
mable, sequence-specific DNA endonucleases now allow 
for precise genome editing in cultured cells and in vivo, 
and improvements and modifications in particular in the 
“clustered regularly interspaced short palindromic repeats” 
(CRISPR)/Cas9 technology occur at breathtaking speed. 
In vivo genome editing now becomes possible, and simul-
taneously, the novel CRISPR/Cas9 applications for basic sci-
ence allow experiments, simply unimaginable just 10 years 
ago [154]. This development coincides with profound 
improvements in bioinformatics and vector development, so 
that cell targeting becomes more efficient and side-effects 
can be better predicted, minimized, and controlled.
This position paper, writing on behalf of the commission 
for experimental cardiology of the German Cardiac Society 
(DGK) and the German Center for Cardiovascular Research 
(DZHK), will summarize the different available options of 
gene editing approaches. It aims at basic and translational 
scientists, and covers the recent advances in gene editing 
technologies and their application in unbiased screens and 
animal studies. Moreover, a perspective for the application 
of gene editing in cardiovascular medicine will be pro-
vided. Finally, the limitations and ethical considerations 
of gene editing will be addressed and an outlook provided 
on the considerations for human genome editing and future 
developments.
The general approach of gene editing
The traditional approaches of gene editing were restricted 
to cells and usually based on the integration of linear DNA 
stretches into the genome, which were provided through 
transfection or microinjection into the cell. This integra-
tion was either targeted, like the technique used for stem 
cell modification during knockout mouse generation or 
random [78]. Both techniques heavily relied on antibiotic-
based selection, as integration was a rare event, and thus, an 
antibiotic resistance gene was integrated into the genome, 
too. Higher integration rates were achieved with retro-viral 
approaches, but site-specific targeting was limited by these 
approaches.
The discovery of programmable, sequence-specific 
nucleases was a paradigm shift for gene editing. Site-spe-
cific modifications of the genetic code at fairly high effi-
ciency became possible, which facilitated the generation of 
designed cellular and animal models. This new era started 
with the development of sequence-specific nucleases such 
as meganucleases, zinc-finger nucleases, and TALENs. Just 
a few years ago, the bacterial CRISPR/Cas9 system was the 
most important addition to this toolbox and rapidly became 
the preferred gene editing method based on its simplicity, 
efficiency, and universality [35]. With these new genetic 
tools, double-strand breaks can be precisely introduced into 
the genome. Depending on the subsequent cellular repair 
mechanism, these double-strand breaks can be utilized to 
create different gene editing varieties [78].
One of the most widely used CRISPR-associated enzymes 
is Cas9, which originates from Streptococcus pyogenes 
(SpCas9). SpCas9 forms a protein–RNA complex, resulting 
in cleavage of double-stranded DNA at target sites. SpCas9 
is guided to this site by a single guide RNA (sgRNA), which 
is formed by the mature CRISPR-RNA (crRNA) and a trans-
activating tracrRNA, and requires the simple protospacer-
adjacent motif (PAM) NGG, to which the dsDNA cleavage 
occurs ~ 3 base pairs 5′ of the PAM (reviewed in [7]). DNA 
cleavage is followed by reparation of the DNA strand breaks 
by the cell, either through non-homologous end-joining 
(NHEJ) or homology-directed repair (HDR) mechanisms 
(Fig. 1a).
CRISPR/Cas applications
For gene editing of cultured cells by the CRISPR/Cas sys-
tem, most commonly plasmid-based or lentivirally guided 
expression methods are used [118, 125]. These systems are 
continuously and rapidly improved in specificity, efficacy, 
and applicability. For example, the Cas9 nickase mutants 
(D10A or H840A) can produce single-strand breaks [65, 94, 
118]; other additions are high-fidelity Cas9 enzymes [72], 
an expanded PAM Cas9 variant called xCas9 [59] and Cas9 
variants with improved proof-reading enhancing homology-
directed repair (HDR) [68]. Systems for temporal and induc-
ible control like photo-activatable CRISPR/Cas9 systems 
[106, 114] or doxycycline-inducible genome editing [41] 
have been developed and user-friendly bioinformatic tools 
have become available to design specific guide RNAs [34].
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Fig. 1  Principle CRISPR/
Cas systems. NHEJ non-
homologous end joining, HDR 
homology-directed repair, PAM 
protospacer-adjacent motif, 
Cas9 CRISPR-associated 
protein carrying two nuclease 
domains, associated genes, 
dCas9 catalytically dead Cas9, 
Cas9 nickase a Cas9 carrying 
only one nuclease domain to 
induce single-strand breaks, 
sgRNA single-guide RNA, 
pegRNA prime editing guide 
RNA, VP64 gene inducer 
protein domain, KRAB gene 
suppressor protein domain
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Addgene, a nonprofit plasmid repository (www.addge 
ne.com), is of great help in the orientation phase of research-
ers as it provides an overview for what other purposes than 
knockout, knockin, and base editing CRISPR/Cas can be 
used. Especially the invention of the catalytically inactive 
dead Cas9 (dCas9), which lacks endonuclease activity and 
therefore does not cleave, but still can be guided to a tar-
get DNA sequence [115], opened a new field of alternative 
applications. One of such applications is CRISPR-mediated 
control of gene expression by, e.g., CRISPR interference 
(CRISPRi). Here, expression of targeted genes is efficiently 
repressed by either blocking or repressing transcription with 
a dCas9–KRAB fusion protein [48, 115]. In CRISPR activa-
tion (CRISPRa), dCas9 is fused to transcriptional activators 
(like VP64) to activate gene expression of the targeted gene 
[40] (Fig. 1b).
dCas9 fusions with epigenetic modifiers can be used 
to alter locus-specific epigenetic modifications like DNA 
methylation, histone methylations, and acetylations [40]. 
Dynamic live cell chromatin imaging profits from fluores-
cently labeled dCas9 to visualize genomic loci in a single-, 
dual-, or multicolor way [29, 91, 92, 116]. Interestingly, 
recent similar developments were initiated focusing on 
Cas13a/C2C2, Cas13b or CasRx/Cas13d, or their catalyti-
cally inactive variants. Importantly, Cas13 enzymes bind 
RNA and not DNA, which opens up new ways to study RNA 
biology [5, 32, 75, 119].
Specifically, for gene editing purposes, fusion proteins 
of dCas9 with other enzymes have been developed: for base 
editing without double-strand breaks, dCas9 was fused to 
cytidine deaminase, which mediates the direct conversion 
of C → T (or G → A) [12, 74]. This technique is more effi-
cient (between 10 and 30%) than the knock-in approach and 
generates fewer unspecific indels [171]. Fusion proteins of 
the Cas9 nickase domain with reverse transcriptase allow a 
specific insertion of a sequence contained in the provided 
RNA into the genome and is called Prime editor approach 
[11, 74] (Fig. 1c).
Clonal expansion and mixed culture
The CRISPR toolbox is currently growing rapidly [154] 
increasing its versatility, usability, and specificity [12, 49]. 
CRISPR techniques in general can be established in most 
labs and are fairly cheap, as many of the required plas-
mids are provided to the scientific community at no cost. 
An important hurdle, yet, is the introduction of the Cas and 
the gRNAs into the target cell. For this, direct injection, 
plasmid-based transfection or virus-based transduction is 
required. Cell lines usually have to be subjected to antibi-
otic-based selection to enrich the transfected cells, a step 
often followed by clonal expansion [169]. This workflow, 
however, is not applicable to primary cells. Such cells have a 
limited growth capacity before entering a senescent state and 
de-differentiate in culture. Moreover, when primary cells 
become too sparse, they often stop growing, so that the cul-
ture does not recover from the antibiotic-based selection. 
Thus, although clonal expansion might be a possibility for 
some cell types, it comes with the price of substantial phe-
notype alterations during the process. Obviously, for non-
dividing cells, selection and expansion are not an option 
at all, and thus, for primary or non-dividing cells, systems 
with high transfection efficiency are needed. Viral delivery 
systems such as vectors based on adeno-associated virus 
(AAV), adenovirus, or lentivirus are able to transduce non-
dividing cells [84]. For cardiomyocytes, AAV vector deliv-
ery enables HDR in murine adult heart tissues and human 
cardiomyocytes differentiated from induced pluripotent stem 
cells (hiPSCs) independently of the cell cycle stage [73]. In 
contrast to AAV, for adenovirus (AdV) vectors, genomic 
integration is rather an exception. In cultured neonate cardi-
omyocytes, however, some limited integration was observed 
for cells which had entered S-phase [73]. Viral vector sys-
tems vary in their packaging capacity, the genetic material 
(DNA/RNA), and the vector genome form. Adenoviral vec-
tors (HCAdV) are rather effective in transduction and have 
a large packaging capacity. They can carry within a single 
vector a whole CRISPR/Cas9 system with gRNAs. The 
system has been successfully used for targeting the human 
papillomavirus (HPV) 18 oncogene E6, the dystrophin gene 
causing Duchenne muscular dystrophy (DMD) and the HIV 
co-receptor C–C chemokine receptor type 5 (CCR5) [42]. 
Very popular vectors are adeno-associated viruses (AAVs). 
They have already been approved for a number of human 
clinical trials, showed only mild toxicity at high doses in 
animal experiments, and are less immunogenic than other 
viruses. Most importantly, AAV displays a safe integra-
tion pattern and long-term persistence in non-dividing cells 
mediating stable gene expression [167].
Regarding the turnout of the gene editing events, the 
impact on the cell population will be diverse. Non-edited 
cells, successful edits, failed edits with chromosomal aber-
rations, and off-target edits will all be present in the small 
culture dish. As a result, in the mixed culture, the functional 
consequences of gene editing on the cellular phenotype will 
not be as pronounced as with clonal expansion. It should, 
however, be mentioned that clonal expansion is only supe-
rior to the mixed culture approach if several clones are being 
characterized and if the clones are carefully studied for the 
above-mentioned limitations. Whereas demonstration of 
the anticipated gene editing event is usually a relatively 
easy task with PCR, the demonstration of the absence of 
off-target editing events is laborious and expensive. Clonal 
expansion is also more prone to artefacts than a mixed cul-
ture approach. A recent study by the Odom lab, comparing 
different loss-of-function methods (siRNA, LNA, CRISPRi) 
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showed that the introduction of the dCas9-KRAB protein 
alone had already strong effects on the transcriptomic land-
scape on a clonal level, whereas the non-clonal cell line 
showed almost no differentially de-regulated genes com-
pared to the parental cell line [144].
The decision on the most appropriate technique for the 
individual purpose should therefore consider the type of cell, 
the transfection efficiency, and the quality of the gene editing 
approach. If the particular cell model under investigation 
permits the expansion of single cells and if efficacy of the 
sgRNAs is an issue, then clonal expansion may be consid-
ered. If the cell system does not permit clonal expansion or 
cannot refrain from natural heterogeneity of, e.g., a primary 
cell population, a polyclonal design may be chosen [128].
CRISPR/Cas screening
Screening technologies are used to uncover dependencies 
and relations targeting a number of interactors followed by 
the acquisition of a specific readout. In unbiased genetic 
screens, expression of a large array of genes is altered ran-
domly, and the subsequent consequences on expression of 
other genes or functional parameters like proliferation or 
differentiation are determined. The CRISPR/Cas system 
has revolutionized the technology of genetic screening as 
unbiased forward and reverse genetic screens with large 
sgRNA libraries targeting thousands of genes in parallel are 
now possible. This technique currently represents the most 
powerful approach to identify genotype-to-phenotype rela-
tionships. To call these interactions, current screens take 
advantage of pioneering RNA interference work performed 
in drosophila [100]. Generally, there are two types of genetic 
screens—positive and negative—in which phenotypes and 
genotypes are either enriched or depleted, respectively 
[39]. These screens can be performed in arrayed and pooled 
conditions (Fig. 2). Arrayed screens have the advantage of 
physically separating genotypes, enabling subcellular and 
morphologic read-outs, but have the disadvantage of becom-
ing quickly unfeasible when automated plate handling and 
phenotype recording is not available [8]. In contrast, pooled 
screens have the advantage that hundreds of thousands of 
genotypes can be tested simultaneously in adherent, suspen-
sion, or three-dimensional culture as well as living animals. 
However, read-outs of pooled screens are currently limited 
to cell fitness effects or depend on phenotypic reporters cou-
pled to cell enrichment steps [98, 124].
The groups of Feng Zhang, David Sabatini, and Eric 
Lander were the first to report the use of CRISPR technol-
ogy for unbiased genetic screening. In these pioneering 
studies, the identification of essential human genes and 
6-Thioguanin and vemurafenib resistance mechanisms 
served as a proof of concept and represented the begin-
ning of the CRISPR screening revolution [131, 159]. Since 
these early reports, technical parameters defining library 
composition (gRNA design rules and number of gRNAs 
per target) and optimal screening conditions [multiplicity 
of infection (MOI) and library representation (coverage)] 
have been identified [108, 127]. Currently accepted condi-
tions include the use of 4–6 highly active gRNAs per target 
gene, delivered to cells with an MOI of 0.2–0.5 and rep-
resented in the experiment with 500–1,000-fold coverage. 
Standardizing these conditions enables the comparison of 
different gRNA libraries and their in-screen performance 
in different cellular model systems. This has vastly con-
tributed to the increase in screening reproducibility [16, 
67, 108, 153]. The majority of reported CRISPR screens 
were designed to identify novel gene to phenotype rela-
tionships, while only few studies investigated functional 
aspects of non-coding sequences [23, 134, 160]. Strate-
gies to efficiently interrogate and functionally annotate 
non-coding regions apply either DNA tiling or excision 
approaches. For both approaches, genomic regions are 
targeted by all possible gRNAs within a given region 
or the DNA connecting two juxtaposed gRNA-target 
sites is excised and lost, respectively [23, 76, 126]. Til-
ing approaches were initially used to identify functional 
domains in proteins, but have since been used successfully 
to find essential nucleotide sequences in predicted promot-
ers, enhancers, and long non-coding RNAs [87, 126, 132]. 
Excision screens are currently limited to a few target sites, 
mostly because no technological solution exists to generate 
pooled gRNA libraries with predetermined gRNA com-
binations [130]. Noncoding sequences make up the vast 
majority of the human genome; hence, it will be important 
to solve this technical issue to enable broader unbiased 
investigations into this “dark” region of the genome.
For CRISPR screens, data recording is robustly and rou-
tinely performed by next-generation-sequencing (NGS), 
while data analysis lacks a broadly accepted approach. 
Several algorithms (e.g., MAGeCK, HitSelect, PinAPL.
py, and ScreenBeam) with differing statistical assumptions 
have been developed, though it is currently unknown which 
pipeline performs most accurately as data on comparing 
hit validation are still missing [37, 82, 142]. Also, most 
of these tools have been repurposed from the analysis of 
RNAseq data and only few algorithms are designed for the 
needs of CRISPR screens. With the increasing number of 
CRISPR screens that aim at identifying gene–gene interac-
tions, CRISPR-tailored data analysis algorithms are needed. 
The search recently culminated in the GEMINI algorithm to 
identify genetic interactions in multiplexed or combinatorial 
CRISPR screens [170]. As the CRISPR screening field is 
moving towards multiplexing, it will be crucial to estab-
lish, similar to single screens, experimental parameters and 
statistical models that enable high reproducibility and hit 
penetrance [38].
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CRISPR/Cas screening in combination 
with scRNA‑Seq
The recent rise of single-cell RNA sequencing (scRNA-
Seq) permitted for further evolution of CRISPR-based 
genetic screens [39, 112]. While pooled screens produce 
rather simple, low-dimensional read-outs such as “growth” 
or “no growth” and typically require validation by further 
experimentation, scRNA-Seq of CRISPR-manipulated cell 
populations employ the transcriptomic signatures of indi-
vidual CRISPR-manipulated cells as high-dimensional, 
complex phenotypes (Fig. 2). The assay principle relies 
on the introduction of “barcode” sequences (or a polyade-
nylated copy of the sgRNA itself) together with individual 
sgRNA sequences, thus permitting the assignment of gene 
expression profiles to the manipulation of defined genetic 
loci in one single experiment. A treatment or selection is 
not necessarily needed to perform such screens (although 
the frequency of the sgRNA still can yield some insight on, 
e.g., lethality of a knockout/knockdown) (Fig. 2).
Editing the genome of hiPSC for advancing disease 
modeling
The advent of human-induced pluripotent stem cell (hiPSCs) 
technology has provided a huge opportunity to establish 
cellular models of disease from individual patients, and to 
study the effects underlying genetic aberrations of inacces-
sible cell types [93, 141, 147]. Particularly, the investigation 
of molecular mechanisms and cellular phenotypes resulting 
from a specific mutation (rather than the individual’s genetic 
background) is possible in iPSC models of disease through 
the correction of mutated genes in diseased iPSCs (isogenic 
controls), or by the introduction of causative mutations in 
healthy iPSCs [17, 140]. It should be emphasized that, con-
trary to monogenic diseases, the dissection of polygenic dis-
orders is more complicated as a large number of genetic vari-
ants are acting in a complex network, and a single variant is 
not sufficient to trigger the disease [97, 99]. A specific chal-
lenge is posed for diseases involving X-linked genes. When 
using hiPSCs to model X-linked developmental disorders or 
inherited conditions that undergo sex-specific modulation of 
penetrance (e.g., autism spectrum disorders), it is crucial to 
consider the course and status of X chromosome inactivation 
(XCI). XCI is a unique dosage compensation mechanism 
that occurs during early embryogenesis and enables equiva-
lent expression of X-linked genes between male and female 
mammals [56]. Reprogramming of female cells can give 
rise to two different hiPSCs: XCI has been maintained as 
in the original somatic cell, or X-chromosomal reactivation 
(XCR) occurs followed by random mosaic or skewed XCI 
in the differentiation state, according to the pluripotent state 
(primed versus naïve) [31, 80, 123]. A third rare outcome is 
an abnormal partial XCR, in which differentiation does not 
yield a fully XCI [149]. The failure to precisely characterize 
XCI status can have significant consequences for the validity 
of hiPSC-based disease models and their implementation 
after genome editing approaches.
Among genome editing technologies, CRISPR represents 
the most electable approach in many cell and tissue types 
[18, 65, 66, 74, 155]. As mentioned earlier, targeted dsDNA 
cleavages are repaired through two different pathways: NHEJ 
and HDR. NHEJ results in insertion and deletion (indel) 
mutations and can be employed to insert a premature stop 
codon, resulting in knockout of the gene. This strategy has 
been recently used to study the deficiency of the KCNA5 
gene, which leads to a lower beating rate and prolonged field 
potential durations of atrial cardiomyocytes [96]. The same 
approach could be used to restore the normal activity of 
genes, for instance deleting expanded CGG repeats of the 
FMR1 gene to rescue Fragile X syndrome [111]. The com-
bination of CRISPR and the PiggyBac transposon systems 
enables the insertion of large modifications needed in cases 
of large deletions such as Duchenne muscular dystrophy and 
Huntington’s disease [86, 165].
HDR-mediated genome editing repairs DNA in a precise 
manner referring to the sister chromatid as template and can 
be used to introduce or correct specific disease-associated 
variants for disease modeling. Correction or introduction 
of disease-associated gene variants (1–20 nt) has recently 
been accomplished with the use of short single-stranded 
oligonucleotide donors (ssODNs) with homology arms of 
30–200 nt [121, 168]. An advantage of ssODNs, besides 
their fast design and generation, is that they are less likely to 
integrate randomly into the genome in comparison to plas-
mids or linear dsDNA donors [83]. The ssODN strategy 
results in scarless editing, but the lack of selectable markers 
encoded within the donor increases the difficulty for iden-
tification of positive clones. Alternative to ssODNs, single-
stranded rAAV DNA templates harbor the beneficial fea-
ture of providing long homology arms and resistance genes 
Fig. 2  CRISPR/Cas screening possibilities. Three strategies have 
been developed for CRISPR/Cas screens: in array screens, single 
wells/dishes of cells are infected with one individual sgRNA each, 
the readout is typically on cellular signature signals, such as com-
paring bulk transcriptomes or performing surface protein expression 
profiles. Pooled screens involve transducing several to many sgRNAs 
and applying a positive or negative selection on transduced cells. Tar-
get genes that generate the desired phenotype are uncovered by deep 
sequencing and subsequent ranking of measured sgRNAs. Third, cells 
expressing any kind of CRISPR/Cas machinery are transduced with 
a pooled sgRNA library. Cells will express a functional sgRNA copy 
together with a second copy of the sgRNA that allows identification 
by sequencing [barcoding, poly(A)-tailing, e.g., used in, e.g., Perturb-
Seq, CROP-Seq etc.]. After droplet sequencing, sgRNA-mediated 
perturbation can be analyzed in single cells. Multiple sgRNAs against 
a target gene are used to validate the phenotype
◂
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for increased recombination efficiencies with low rate of 
genomic integration. Moreover, CRISPRa/i approaches are 
useful in treating human diseases due to haplo-insufficiency 
or protein accumulation such as Parkinson and Alzheimer’s 
disease [57].
Overall, genome manipulation of hiPSCs has become 
highly efficient using CRISPR, especially for NHEJ-based 
pathways (80–90% with NHEJ vs < 10% with HDR). None-
theless, Cas9 can bind off-target sites with mismatches, 
resulting in variable off-target activities [151]; Cas9 con-
struct is either permanently integrated [24, 50] or remov-
able with a subsequent reagent delivery and/or clonal selec-
tion step [164] to achieve scarless editing. Alternatively, 
non-integrating methods include Cas9 ribonucleoprotein 
(RNP) complexes, which are immediately active and rap-
idly degraded over a period of around 12 h [69], reducing 
the potential for off-target mutagenesis and re-targeting after 
successful HDR.
Repairing causative lesions in patient-derived iPSCs 
which are subsequently differentiated towards specific cell 
types might be used for cellular therapy treatment. Some 
strategies are promising, e.g., injection of autologous iPSC-
derived dopaminergic neurons in the treatment of a chemi-
cally induced primate model of Parkinson’s disease [55]. 
Nevertheless, various technical hurdles and biological ques-
tions need to be addressed before the introduction of thera-
peutic use of CRISPR/Cas in humans.
Genome editing in animals
Genome editing and disease modelling in zebrafish
TALEN and CRISPR/Cas9 are meanwhile the standard tools 
for reverse genetics in zebrafish (Fig. 3). Originally, Cas9 
and a single sgRNA were used to target a specific region 
within the gene of interest forming insertion/deletions 
(indels), premature stop codons, or frameshifts, which inac-
tivate the generation of a functional gene product [26, 35, 60, 
95]. Depending on the position of the premature stop, non-
sense-mediated decay of transcribed RNA and production 
of small RNA fragments may trigger the expression of genes 
that can compensate for the mutation and mask the pheno-
type [44]. Such compensation mechanisms, which are also 
operational in mice, account for the discrepancy between 
morpholino knockdown and mutant phenotypes. The cur-
rent consensus for generating a mutant therefore is to sup-
press the RNA transcription of the target gene completely, 
thereby avoiding the formation of RNA decay products and 
compensation. This is achieved by either deleting the full 
gene locus, or by removing the complete transcriptional or 
translational start regions using a combination of two sgR-
NAs. In general, control experiments suitable to uncover 
potential compensation do not target the gene but rather its 
expression, like CRISPRi or shRNA.
CRISPR/Cas9 is also used for knock-in approaches in 
zebrafish [14, 19, 70]. The knock-in can be utilized to gener-
ate specific—patient similar—mutations, or repair existing 
mutations [148]. The current limitations of this technique 
are the low efficiency (between 0.5 and 1%) and the addi-
tionally generated off-target mutations. Base-editing, for 
example by a fusion of dCas9 with cytidine deaminase, has 
a higher efficiency (10–30%) and greater specificity [171].
Genome editing and disease modelling in mice
Similar to zebrafish, also in mice, the CRISPR/Cas9 system 
replaced classical genetic engineering techniques to gener-
ate different genome-engineered transgenic mouse lines [52, 
78, 89]. Cas9 is the most widely used nuclease due to the 
simple protospacer-adjacent motiv (PAM) 5′-NGG-3′ and 
the generation of double-strand breaks (DSB) compared to 
Cas12a (Cpf1), which has a PAM (5′-TTN-3′) that is T-rich, 
less frequent in the genome and creates staggered ends [28, 
107]. Among the mutations generated are classical and con-
ditional gene knock-outs (KOs), knock-ins (KIs) at specific 
genomic loci as well as point mutations or epitope insertions 
in desired gene regions. The efficiency of gene modification 
at specific loci using the NHEJ mechanism reaches almost 
90% and the efficiency of KI using the HDR mechanism is 
up to 50%. To increase HDR frequency, different strategies 
Fig. 3  Domains of gene editing in animals. Whereas Cas9-mediated 
germline gene editing now becomes the standard technology for the 
generation of transgenic fish and rodents, larger mammals, like trans-
genic pigs are still generated by “conventional” technology. Pigs and 
dogs are important laboratory animals in the translational avenue to 
established somatic gene editing for clinical use
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to inhibit NHEJ and to enhance DNA repair mechanisms 
are implemented (for review, see [35]). Nevertheless, these 
rapidly evolving techniques still contain serious limitations 
exemplified in several KI experiments by the creation of con-
ditional KO mouse alleles. All gene-targeting protocols are 
performed by direct injection of CRISPR/Cas9 components 
together with donor DNA template into fertilized oocytes. 
For KI experiments, comparatively long-donor DNA frag-
ments (~ 600–1650 nt) are utilized employing either single-
stranded (ssDNA) or double-stranded (dsDNA) templates. 
Efficiency of homologous donor DNA template integration 
into the locus is variable and correlates with template size 
and the locus. In general, longer DNA templates integrate 
less efficient than shorter ones.
Attention should be paid to the fact that most genome 
edited mice obtained from CRISPR/Cas9-modified zygotes 
(F0 generation) exhibited mosaic genotypes. The mosaic 
genotype can harbor subpopulations of germ cells derived 
from different DNA-editing events, and contain diverse copy 
numbers of DNA template integrations into the targeted loci 
[136]. The latter suggests that PCR amplification of short 
flanking genomic regions together with parts of the inserted 
artificial sequences, including the LoxP sites in template 
DNA, is the most efficient and reliable approach for the 
identification of F0 mice with a correctly targeted event. 
When the selected F0 founders were crossed with wild-type 
mice to obtain F1 offspring, animals harboring multiple 
head-to-tail integrations (MHTI) of the donor DNA tem-
plate at the targeted locus can be detected frequently. These 
DNA template multiplications occur irrespectively of the 
size, nucleotide composition, or the utilization of dsDNA 
or ssDNA [136, 138].
Importantly, a commonly used PCR analysis method of 
heterozygous animals, employing locus-specific oligonu-
cleotides located outside of the targeted homology region, 
would under this condition, in most cases, mistakenly indi-
cate a single-copy integration event. Southern blot analysis 
is an efficient accompanying method to reliably identify the 
desired single-copy targeted events in F1 offspring. It is rec-
ommended to include two different specific restriction endo-
nuclease sites flanking the LoxP regions. This will allow 
the detection of correctly targeted events by restriction frag-
ment length polymorphisms (RFLP), using these restriction 
enzyme sites, and also detects the MHTI. In addition, a PCR 
approach with reverse orientation of DNA template-specific 
primers, qPCR, or the ddPCR (droplet digital PCR) can be 
alternative methods for detection of MHTI of the DNA tem-
plate [136]. To exclude any genome alterations, sequencing 
of the entire locus is required.
Genome editing and disease modelling in large 
animals
Large animals are important model organisms to bridge 
between basic science studies and clinical applications. In 
the cardiovascular system, this has been exemplified for 
mutations of the dystrophin gene leading to Duchenne’s 
muscle dystrophy (DMD). A number of mouse models 
have demonstrated efficacy of an AAV-based CRISPR/Cas9 
approach to edit the dystrophin gene. In the mdx mouse, 
excision of the mutated exon 23 suffices to enable expres-
sion of a shortened, but stable dystrophin gene [43, 88, 105, 
146]. Functional assessment, though limited due to a mild 
phenotype of the mouse model, suggested improvement of 
the skeletal and heart muscles after local or systemic vector 
application.
Extending this evidence, Amoasii from the Olson lab [10] 
applied single-guide RNAs and SpCas9 AAV into DMD 
dogs (lacking exon 50), either intramuscularly (i.m.) or 
intravenously (i.v.), and found robust DMD expression at 
the injected sites (i.m.) and also in the heart (i.v. approach). 
Functional consequences of this approach though were not 
reported yet.
In a complementary transgenic pig model lacking exon 
52 of the dystrophin allele, an intein-split version of SpCas9 
[150] was used together with a vector containing a pair of 
gRNAs capable of excising exon 51 also using AAV technol-
ogy [103]. The intein-split approach bypasses the packing 
limit of AAVs: two virus particles are generated which both 
carry a gRNA and the C-terminal and N-terminal, respec-
tively, part of Cas9. Only after a double infection of a cell, 
a complete Cas9 is produced [150]. After i.m. injection, the 
intein-split-Cas9-gRNA approach was efficient in editing up 
to 78% of the muscle nuclei analyzed. Upon i.v. injection, 
7% of the cardiac genomes were edited, resulting in a reduc-
tion of sudden cardiac death of the animals [103].
Delivery of CRISPR/Cas9 in somatic tissue
Besides off-target activity which will be discussed in the next 
section, the aspect of a safe and efficient delivery of the gene 
editing tools is crucial in a therapeutic context. Although 
a number of different approaches have been developed to 
facilitate direct Cas9 ribonucleoprotein complex delivery by 
utilizing nanoparticles, extracellular vesicles, or cell pene-
trating peptides (for review, see [22, 166]), many therapeutic 
approaches are relying on the delivery of genomic encoded 
tools via viral systems (Fig. 3). In this context, the AAV 
system is advantageous due to its capability to transduce 
both proliferating as well as post-mitotic cells, its diverse tis-
sue tropism, its robust and prolonged expression levels, and 
its relatively low immunogenicity [13]. Nevertheless, the 
maximum packaging capacity of about 4.7 kb resembles a 
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limitation for single vector approaches, especially if the rela-
tively large Streptococcus pyogenes variant of Cas9 is used. 
To overcome this limitation, either the co-administration of 
a Cas9 virus plus a separate gRNA expressing virus or the 
utilization of a split-Cas9 system can be helpful [13].
The previously described therapeutic studies for DMD 
exemplify these different strategies: the group of Eric Olson 
applied a single cut approach to restore the reading frame 
of exon 52 deficient dystrophin by insertions or deletions 
(Indels) in the 5 prime region of exon 51, and partially also 
by enhanced skipping of exon 51. The group of Christian 
Kupatt follows a different approach utilizing the split-intein 
system (Fig. 4). Here, two distinct AAV constructs, each 
harboring one individual gRNA under the control of an U6 
promoter and one half of the intein-fused SpCas9 nuclease 
under the control of a pol-II promoter, are co-injected. Upon 
co-expression in the same cell, the N- and C-terminal halves 
reconstitute and perform guided nuclease activity analogous 
to wild-type Cas9 [103]. This setup allows the delivery of 
SpCas9 together with two independent gRNAs and is only 
active in co-transduced cells. Instead of one gRNA located in 
exon 51, two gRNA in the intronic regions flanking exon 51 
have been selected to precisely excise the exon and thereby 
restoring the reading frame. In general, these exon snip-
ping approaches allow a more flexible design of the utilized 
gRNAs and thus enable a more stringent selection regard-
ing predicted off-target activity. Furthermore, compared to 
full length Cas9 approaches, this system has the potential 
to operate under the combined control of two distinct, tis-
sue and/or cell type-specific pol-II promoters, which further 
enhances not only the specificity but also the safety of the 
gene therapy approach. Apart from this, in general, every 
aspect of a gene therapeutic approach has to be optimized 
to achieve the highest level of safety. This includes an effi-
cient and safe delivery of the tools, a specific expression of 
a Cas9—ideally restricted to the tissue/cells of interest and 
preferably a temporal restriction of the gene-editing event.
Analysis of CRISPR/Cas9 off‑targets
Beside the thorough characterization of the targets, off-target 
events deserve closer attention. Programmable nucleases 
such as CRISPR/Cas9 are efficient to generate on-target 
genetic modifications; however, rigorous design of sgR-
NAs, Cas9, and delivery modes are necessary to minimize 
potential off-target genomic alterations and to ensure the 
integrity of the genome of manipulated cells (for review, 
see [62]). To facilitate the use of crRNA, representing 20 bp 
complementary sequence to the target genomic region and 
tracrRNA (trans-activating crRNA) representing a scaffold 
to bind Cas9 both have been combined into a sgRNA [66]. 
It has been reported that even 3–5 mismatches at the distal 
(5′) end of the protospacer sequence can be tolerated leading 
to DSB [46]. Thus, if sgRNAs are not properly designed, 
off-target effects might be induced.
To minimize off-target activity and increase specificity, 
truncated guide sequence at the distal 5′ end [45] was shown 
to be beneficial so is chemical modification at the 3′ end 
of gRNA [102]. In addition, a number of web tools have 
been designed for proper design of gRNAs taking also PAM 
sequences into account and to identify potential off-targets 
genome wide, e.g., CRISPRdirect [104], Cas9 design [90], 
and ChopChop [39, 101]
Based on the three-dimensional structure of Cas9, 
mutants (D1135E) have been generated which increase 
on-target specificity and recognize [71] different PAM 
sequences of different lengths, thereby increasing specific-
ity. Furthermore, Cas9 nickase mutants have been developed 
in which the RuvC or HNH nuclease domain is inactivated 
resulting in juxtaposed single-stranded nicks [79], or a pair 
of catalytically inactive dCas9 nucleases each fused to FokI 
nuclease domain [26, 113]. Each of these approaches reduce 
off-target mutagenesis; however, they also have their limita-
tions with respect to cleaving efficiency, e.g., double nick-
ing requires two guides and truncated guides can reduce 
Fig. 4  Split-Intein-AAV-System: due to the packaging limit of 
adeno-associated virus (AAV), the most-frequently used Cas9 genes 
together with two guide RNA cannot be transducted by a single AAV. 
In the Split-Intein-System, the cell is infected with two different 
viruses, both containing one part of Cas9 and one part of the Intein 
gene. Expression of both constructs yields a complete, enzymatically 
active Cas9
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on-target efficiency, as well. Using structure-guided protein 
engineering in combination with unbiased whole-genome 
off-target analysis, enhanced efficiency variants of Strep-
tococcus pyogenes Cas9 (eSpCas9) have been generated 
which exhibited reduced off-target and robust on-target 
effects [137].
Reduction of off-target mutagenesis can also be achieved 
via temporal expression of Cas9 taking advantage of a tet-
racycline responsive promoter [137], using split-Cas9 intein 
system [137], and by inactivating Cas9 through self-cleavage 
providing in addition Cas9-specific gRNA [137].
Different methods are available to search and inspect 
potential off-target sites. There are three main strategies 
available: (1) to determine sequences of potential off-target 
sites; (2) to determine potential DSBs genome wide; (3) to 
determine genome integrity.
The first straightforward strategy is to determine predicted 
off-target sites using software and assay the PCR products 
for mismatches by single-strand annealing and endonucle-
ase treatment (e.g., T7EI, Surveyor nuclease assay). These 
techniques are most commonly used as they are easy to 
implement and cost effective. Alternatively, deep sequenc-
ing of exome genome wide (all protein coding regions) is 
performed to identify potential mutations in protein coding 
genes [148]. A more in-depth analysis is achieved by whole-
genome sequencing (WGS) used in cell lines [139, 145, 156] 
and mice [64]. These techniques are powerful and allow to 
identify small indels but not large genomic rearrangements. 
Larger genomic rearrangements and CNVs need to be exam-
ined using alternative methods, e.g., fluorescence-in-situ-
hybridisation [20].
Second, identifying potential DSBs by chromatin immu-
noprecipitation and pull-down of DNA fragments (ChIP-
seq) have been employed in different flavors, e.g., using 
dCas9 to determine Cas9-binding sites [162]. Alternatively, 
strategies have been developed which label DSB by either 
streptavidin-biotinylated linkers [33] or by incorporating 
short phosphorylated double-stranded oligodeoxynucleo-
tides (GUIDE-seq [152]). An elegant extension of these 
strategies is the DISCOVER-seq (discovery of in situ Cas 
off-targets and verification by sequencing) method that lever-
ages on the recruitment of DNA repair factors in particular 
MRE11, which binds closely around the Cas9 cleavage site, 
to uncover Cas9 activity [161].
Additional technologies are useful to confirm the results 
obtained by CRISPR/Cas9: Despite having their own poten-
tial off-target effects, RNA interference with different siR-
NAs/shRNAs, the use of different (morpholino) antisense 
oligonucleotides, and LNA GapmeRs, as well as different 
pharmacological inhibitors should be taken into considera-
tion to validate on-target effects seen by CRISPR/Cas9-
mediated knockout or inhibition experiments and to further 
rule out the possibility of off-target effects. In the case of 
CRISPR/Cas9-mediated activation systems, plasmid- or 
viral-overexpression systems can be used for clarification. 
Moreover, as mentioned before in the section regarding 
clonal expansion, but not only concerning mixed popula-
tions, several clones of the control and the mutants should 
be characterized carefully to rule out off-target effects and to 
strictly define the limitations of the systems. Another way is 
to test directly the expression of genes which were predicted 
in the gRNA web design tools. For genome editing in mice, 
back crossing the transgenic mice generated by CRISPR/
Cas9 could help to reduce the chance of off-target effects.
Thus, as with other genome and nucleic acid interfering 
techniques, we should be cautious with results obtained by 
CRISPR/Cas9. A broad set of tools is already available to 
reduce and detect off-targets and maintain robust on-target 
mutation. Selection of the strategy depends on the experi-
mental setup, e.g., cell lines, animal models, preclinical gene 
therapy models, and whether an ex vivo or in vivo gene ther-
apy approach is taken. In case of genome editing in model 
systems, potential off-targets can be reduced simply by back 
crossing wild-type animals to the F2 generation. In addition, 
at least two independently established mutants should be 
phenotypically characterized. For an in vivo gene therapy 
approach, rigorous experimental design and pretesting of 
gRNA, ideally in patient-derived cells, are required as well 
as applying high-end design, optimized endonucleases, opti-
mized delivery strategies, and validation tools to minimize 
potential off-targets. Irrespective of all precaution measures, 
there is still an unforeseen risk of generation of by-stander 
mutations in the genome.
Considerations for clinical gene editing
Clinical translation and thus disease treatment are the ulti-
mate aim of many gene therapy approaches. Several clini-
cal studies with zinc-finger nucleases or later on TALENs 
have been initiated since 2009. They focused on a variety of 
conditions such as cancer, HIV, and hematological diseases 
with the outcomes still to be reported in most cases [84, 
109]. In the last years, first clinical trials with CRISPR/Cas9 
approaches have started to recruit patients (Fig. 5). Impor-
tantly, recent preliminary results from a clinical phase I trial 
showed that gene editing using CRISPR/Cas9 might be safe 
and feasible to apply [143]. T-cells from three patients with 
different types of advanced cancers were gene edited by 
CRISPR/Cas9 ex vivo using electroporation, resulting in 
ablation of three proteins that could inhibit the T-cells’ abil-
ity to target tumor cells. In a second step, a cancer-specific 
T-cell receptor transgene was expressed in these cells by 
lentiviral gene transfer to recognize a particular epitope on 
tumor cells. After administration into the respective donors, 
gene-edited T-cells were engrafted and persisted for at 
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least 9 months without significant side-effects. As cancer 
continued to progress in all three patients, the question of 
efficiency of the gene-edited T-cells against advanced can-
cer remains open. In this particular trial, gene disruption 
efficiency was 15–45%, based on the techniques available 
at the time the study was approved (2016), whereas newer 
techniques allow now > 90% of gene disruption [122, 129]. 
Apart from the preliminary CRISPR/Cas9 clinical data, fur-
ther gene editing studies in patients have been initiated aim-
ing at elimination of mutations that lead to the development 
of cancer or hereditary diseases such as sickle-cell anemia, 
beta-thalassemia, or Leber congenital amaurosis [84]. The 
selection of human diseases currently treated with gene edit-
ing approaches, however, also illustrates the current bottle-
neck of clinical gene therapy: delivery of the CRISPR/Cas9 
system and the sgRNA in patients.
While efficiency is already a major hurdle in clinical tri-
als of gene therapy in general and in particular for cardiac 
diseases [63, 85], specificity of gene transfer is of decisive 
importance for gene editing approaches considering poten-
tial off-target effects such as chromosomal translocations and 
rearrangements with at least a theoretical oncogenic poten-
tial. Therefore, current studies in patients predominantly 
focus on ex vivo gene editing (i.e., cell therapy), for exam-
ple in hematopoietic stem cells for sickle-cell anemia or 
T cells for novel cancer therapies, where the gene-edited 
cells can be reinfused into the body. In addition, ex vivo 
delivery allows a transient transfer of Cas9 and sgRNAs by 
electroporation that results in almost an absence of residual 
Cas9 activity in the cell product [143]. This might be impor-
tant not only to limit the duration of Cas9 activity for safety 
reasons, but also to avoid immunological clearance of the 
gene-edited cells due to development of a humoral response 
to Cas9.
It is not surprising that the first clinical study using viral 
vectors for delivery of Cas9 and sgRNAs in vivo aims at 
treating a particular form of Leber congenital amaurosis [4], 
in which the coding sequence of the defective gene is too 
large to be packaged in a viral vector for the conventional 
overexpression. The eye is an immune privileged and easily 
accessible organ which allows efficient subretinal injection 
of AAV vectors as previously shown in a successful clini-
cal study: a classical AAV-based gene replacement strategy 
revealed improved vision in patients with congenital amau-
rosis due to deficiency of a protein required for photorecep-
tor function [15].
While rapid clinical translation of the CRISPR/Cas9 tech-
nology is impressive, several limitations need to be over-
come before gene editing approaches can be applied for car-
diovascular diseases. Target cells such as cardiomyocytes 
require an efficient in vivo delivery system consisting of a 
suitable vector (for example, AAV vectors), but also a suita-
ble application system for transvascular gene transfer such as 
coronary venous retroinfusion for cardiac transduction [63, 
117]. Considering that any transvascular vector application 
results in some systemic spill-over, unwanted side-effects 
need to be prevented by confining expression of gene editing 
elements to the target tissue, for example, by use of tissue-
specific promoters or alternative detargeting approaches [47, 
63]. Alternatively, ex vivo gene editing therapies of whole 
organs (i.e., heart or lung), for which short time artificial 
organ support is possible, can be a first step towards clinical 
application in cardiac or pulmonary diseases.
Even if gene transfer into less immune privileged organs 
such as the heart would be efficient with viral vectors and 
appropriate delivery systems, it is not clear whether Cas9—a 
bacterial protein—will trigger an adaptive cellular immune 
response. Furthermore, also preexisting humoral reactivity 
to Cas9, which was previously detected in serum of healthy 
individuals, could affect sustained expression of Cas9 in 
transduced cells [27, 135, 158]. Thus, it might be necessary 
for in vivo gene editing in less immune privileged organs to 
control Cas9 gene expression using inducible promoters or 
switch to vector systems that enable an only transient Cas9 
expression.
Fig. 5  Concepts of human genome editing
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Beside the immunological effects of the Cas9 enzyme, a 
further limitation towards broad clinical translation of the 
CRISPR/Cas9 system might be the p53-mediated response 
to double-strand breaks induced by CRISPR/Cas9, leading to 
a principally but not widely proven enrichment for P53-defi-
cient and thus more cancer-prone cells [53, 61]. Moreover, 
target recognition is prone to error, so that gene editing may 
introduce changes at partly unpredictable off-target sites 
due to similarities to the target recognition sequence. Even 
more alarming is that repair of double-strand breaks induced 
by gene editing approaches leads to large deletions, inser-
tions, or complex rearrangement events involving the target 
site [77]. These unintended edits are detected consistently 
[6, 110, 133, 163, 173] and highlight the need for accurate 
genotype characterization, as these potentially have devas-
tating outcomes in clinical tests. The repertoire of molecu-
lar, genetic, and next-generation-sequencing techniques to 
analyze (CRISPR/Cas9-mediated) changes on the genome 
is large and sufficient for verification of editing success and 
prevention of unwanted events. The opinion article by Bur-
gio and Teboul [21] provides assistance and advice for the 
application of CRISPR/Cas9. Accurate predictions and the 
understanding of the whole range of possible editing out-
comes are critical for the continuous success of CRISPR/
Cas9.
Numerous approaches to increase specificity of gene 
correction have been undertaken focusing on optimiza-
tion of the gRNA or the nucleases used for gene editing 
itself [59]. These improvements include the development 
of small molecule tunable Cas9 enzymes [36]. Also new 
variants of Cas nucleases, such as xCas9 and SpCas9-NG, 
enable the targeting of alternative PAM sequences and thus 
expand the range of genomic loci that can be edited [10, 
143]. Fusion of nucleobase deaminase enzymes to catalyti-
cally inactive Cas variants makes it possible to accomplish 
mutual conversion among four bases [51, 74, 81, 172]. These 
so-called “base editors” modify base pairs at specific sites, 
thereby expanding the potential applications of the CRISPR/
Cas system to correct disease-associated single nucleotide 
polymorphisms. Cytosine and adenine DNA base editors 
(CBE, ABE) and their approximate editing windows have 
been described in [120]. Both could be useful tools also to 
install or correct pathogenic point mutations. CBEs mutate 
C•G-to-T•A by binding to genomic target regions and 
R-loop formation. They bind to a target DNA sequence and 
form a single-stranded R-loop, and the covered cytosines 
are deaminated to form uracil bases. Uracil glycosylases are 
inhibited by the uracil glycosylase inhibitor domain and the 
Cas9 domain regulates DNA repair leading to an adenine 
opposite the uracil. ABEs mutate A•T-to-G•C by deami-
nating target deoxyadenosines to deoxyinosines, regulating 
the direct DNA repair to install a cytosine opposite the ino-
sine nucleoside [12]. A recent development called “prime 
editing” showed less off-target editing without introducing 
double-strand breaks or donor DNA by fusing a catalytically 
inactive Cas to an engineered reverse transcriptase [11]. 
Editing individual bases in RNA offers also great potential 
in medicine. Adenosine conversion to inosine, which is gen-
erated by the adenosine deaminases from the ADAR family, 
has been shown to be a useful tool using both antisense and 
Cas13-guided RNA-targeting methods [120]. If and when 
these improvements (see also Fig. 1) may enter clinical tri-
als is not known.
In summary, development of therapeutic gene editing 
approaches requires a careful design of the genome edit-
ing strategy including the most appropriate Cas variant, an 
appropriate vector system, and mode of vector delivery.
Clinical perspective of gene editing
Considering the fast pace of clinical translation of gene edit-
ing approaches and but also the many open safety questions, 
the question of the best way to clinical translation emerges. 
It is current consensus that clinical trials can be started 
now and that these should aim on advanced cancers or rare 
hereditary diseases, for which efficient gene delivery modes 
are well established. These early studies enable collection of 
safety data which is highly needed for further studies with 
improved gene editing tools.
It is important to stress that gene editing techniques—as 
all other advanced therapeutics—require continuous con-
sideration of social, ethical, and regulatory issues. How-
ever, increasing commercial interests may cause conflicts of 
interest preventing unbiased dissemination of methods and 
results. Instead of being published in peer-reviewed journals, 
results of commercial research and trials executed by com-
panies are rather disseminated in business statements and 
announcements on websites [25, 109]. However, full dis-
closure of methodologies and concise analysis of off-target 
effects will remain necessary to assess the impact of any 
novel gene editing approach and to establish trust for further 
clinical translations.
Although apparently technically feasible, there is broad 
consensus among stakeholders that gene editing needs to 
be restricted to somatic cells as there are significant ethi-
cal, scientific, and socio-economic concerns regarding ger-
mline genome modification [9, 30]. As for all gene therapy 
approaches, Germany and many other countries have issued 
a strict ban on application of techniques for the purpose of 
human germline modification.
Legislation of gene editing approaches in somatic cells 
follow those for gene therapy products. As ex vivo gene 
therapy requires reapplication of genetically modified cel-
lular products into the patient, these products must also 
comply with both cell-based medicinal product and gene 
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therapy product guidelines and regulation. Details regarding 
the regulations of gene therapy products are reviewed else-
where [54]. In Germany, two studies investigating ex vivo 
somatic gene editing for treatment of beta-thalassemia 
(NCT03655678) [2] and sickle-cell anemia (NCT03745287) 
[3] have already been approved to be conducted.
To further improve safety of gene editing approaches, 
several organizations, including the World Health Organi-
zation, as well as recognized standards developing organi-
zations such as the US National Institute of Standards and 
Technology Genome Editing Consortium, the US Pharmaco-
peia, and the International Organization for Standardization 
(ISO) formulate gene editing standards [9]. Such standards 
are urgently needed to address key concepts like off-target 
effects and their impact on tumor suppressors and onco-
genes. In addition, national and supranational regulatory 
organizations such as the Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA) already 
provide guidance for the development of gene editing tech-
niques for therapeutic modification of somatic cells.
While six gene therapy products have already been 
approved by the FDA and EMA since 2016, more than 
2000 are in different stages of clinical approval including 
several gene editing approaches [1, 58, 84]. Considering 
the enormous development costs and high prices of cur-
rent gene therapy products, socio-economic conflicts can 
be foreseen. While ex vivo gene editing of immune cells 
might be commercially exploited as cancer treatment, 
reimbursement for gene editing approaches focusing on 
rare diseases with individual mutations might become 
more challenging. Thus, reduction of costs for develop-
ment and production of gene therapy products is neces-
sary to allow individualized gene editing therapies for rare 
genetic cardiovascular diseases in the future.
In conclusion, within a few years, gene editing devel-
oped from a scientific concept into everyday research 
reality which now enters the clinic. This development 
is occurring with breathtaking speed, also owing to the 
progress in shuttle development, sequencing technology, 
and bioinformatics. Whereas gene editing just revolution-
ized basic science, it will soon revolutionize medicine. 
This will open up treatment avenues for fatal diseases, and 
cures for many inherent diseases.
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